For two companies the FDA PRO Guidance leads to similar but different measures

A case study in psoriasis

Mordin, M., Brown, T., McLeod, L., DeMuro, C., & Gnanasakthy, A. (2015). For two companies the FDA PRO Guidance leads to similar but different measures: A case study in psoriasis. Value in Health, 18(3), A111-A111. https://doi.org/10.1016/j.jval.2015.03.653

Abstract

The objective of this research is to evaluate whether the 2009 FDA PRO Guidance leads to development of similar measures when followed by different researchers in the same disease. Psoriasis was selected as a case study, because two companies recently published patient-reported outcome measures to assess the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) and the Psoriasis Symptom Diary (PSD).

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article

The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article

Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article

SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia